ERBB2 and breast carcinoma: In breast cancer patients receiving neoadjuvant chemotherapy, no significant differences in chemosensitivity or prognostic outcomes were observed between HER2-low and HER2–0 tumors, considering HR expression subtypes and other current clinicopathological features.